Search PubMed⌕ Search

Biomedical subjects

D Huggins

Publications and source records attributed to D Huggins.

82 records · Page 5Linked to original sources
PubMedDate not supplied

[Cholecystopathy in sickle cell anemia].

The authors analyze the experience with the association of the gall-bladder disease and sickle cell anemia in ten cases. The incidence of this association in these cases was higher, about 80% (eight patients). Because of the increased frequency of cholecystitis and cholelithiasis in this disease, cholecystography (oral or endovenous) is indicated in every patient with sickle cell anemia or another hereditary (Hemolytic jaundice).

Adolescent↗
PubMedDate not supplied

[Clinical trial of etophamide in the treatment of chronic intestinal amebiasis].

The author present the results obtained in the treatment of 100 patients suffering chronic intestinal amebiasis, employing a new drug--Etophamide, in a dose of 1,0 g per day, for three consecutive days. The tolerance of a new antiamebic drug was excellent in all patients, and the parasitological cure rate obtained was 92%. The author concluded that the new derivate amebicide used in this research is very effective for treatment of intestinal amebiasis infections.

Acetamides↗
PubMedDate not supplied

[New derivative of nitromidazole-tinidazole, for the treatment of giardiasis].

The author treated 100 patients infected by Giardia lamblia with a new antiprotozoal agent: Tinidazole. The patients were divided in two groups: Group I, composed of 50 patients were divided with a dosage of 300 mgm per day for seven consecutive days. The author obtained a cure rate of 96% (48 cases), and minimal side-effects were observed in 10% of the cases: nausea and headache, Group II also composed of 50 patients which were treated with a single dose of 2,0 gm. The parasitological cure obtained was around 90% (45 patients) and the tolerance to the drug was very good. To evaluate the cure, the methods of Faust et al. and Hoffman, Pons & Janer, such as spontaneous sedimentation in water, were used, 7, 14 and 21 días after treatment. The author concluded that the new antiprotozoal agent is an excellent drug against Giardia lamblia infections.

Administration, Oral↗